Online citations, reference lists, and bibliographies.
← Back to Search

Patient Selection For Cytoreductive Surgery.

T. Grotz, K. Fournier, P. Mansfield
Published 2018 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
The peritoneal malignancies span the biologic spectrum of aggressiveness from the indolent growth pattern and superficial nature of well-differentiated mucinous appendiceal adenocarcinoma to the rapidly growing and invasive nature of poorly differentiated signet ring cell adenocarcinomas of the appendix, colon, and stomach. An understanding of the biology, distribution, and volume of disease is critical to appropriately selecting patients for cytoreduction and HIPEC with the goal of long-term survival. Herein the authors discuss appropriate the evaluation and selection of patients for with peritoneal surface malignancies for cytoreduction and HIPEC.
This paper references
10.1245/s10434-014-4111-x
Institutional Learning Curve of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Peritoneal Malignancies
P. Polanco (2014)
10.1245/s10434-013-3223-z
Morbidity and Mortality of Cytoreduction with Intraperitoneal Chemotherapy: Outcomes from the ACS NSQIP Database
E. Bartlett (2013)
10.1001/jamasurg.2013.3640
Surgical outcomes of hyperthermic intraperitoneal chemotherapy: analysis of the american college of surgeons national surgical quality improvement program.
M. D. Jafari (2014)
10.1245/s10434-008-9966-2
8-Year Follow-up of Randomized Trial: Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Patients with Peritoneal Carcinomatosis of Colorectal Cancer
V. Verwaal (2008)
10.4251/wjgo.v2.i2.85
Multidisciplinary therapy for treatment of patients with peritoneal carcinomatosis from gastric cancer.
Y. Yonemura (2010)
10.1245/s10434-009-0866-x
Impact of the Peritoneal Surface Disease Severity Score on Survival in Patients with Colorectal Cancer Peritoneal Carcinomatosis Undergoing Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy
T. Chua (2010)
10.1245/s10434-017-5938-8
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Moderately and Poorly Differentiated Appendiceal Adenocarcinoma: Survival Outcomes and Patient Selection
T. Grotz (2017)
10.1016/j.jss.2015.08.003
Feeding tube placement during cytoreductive surgery and heated intraperitoneal chemotherapy does not improve postoperative nutrition and is associated with longer length of stay and higher readmission rates.
Sean P. Dineen (2016)
10.1097/DCR.0000000000000149
Postoperative Complications After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Affect Long-term Outcome of Patients With Peritoneal Metastases From Colorectal Cancer: a Two-Center Study of 101 Patients
D. Baratti (2014)
10.1097/DCR.0000000000000589
Intraperitoneal-Free Cancer Cells Represent a Major Prognostic Factor in Colorectal Peritoneal Carcinomatosis
B. Trilling (2016)
10.1245/s10434-013-3224-y
Efficacy of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy in the Management of Malignant Ascites
Reese W Randle (2013)
10.1016/j.nut.2012.01.017
Impact of preoperative nutritional support on clinical outcome in abdominal surgical patients at nutritional risk.
Bin Jie (2012)
10.1245/s10434-015-4958-5
Laparoscopy is Safe and Accurate to Evaluate Peritoneal Surface Metastasis Prior to Cytoreductive Surgery
R. Marmor (2015)
10.1245/s10434-011-1631-5
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Improves Survival of Patients with Peritoneal Carcinomatosis from Gastric Cancer: Final Results of a Phase III Randomized Clinical Trial
X. Yang (2011)
10.1186/1477-7819-12-270
Role of laparoscopy in patients with peritoneal metastases considered for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC)
T. Jayakrishnan (2014)
10.1245/s10434-015-5081-3
Patients with Peritoneal Carcinomatosis from Gastric Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is Cure a Possibility?
C. Chia (2015)
10.1245/s10434-015-4446-y
A Simplified Preoperative Assessment Predicts Complete Cytoreduction and Outcomes in Patients with Low-Grade Mucinous Adenocarcinoma of the Appendix
Sean P. Dineen (2015)
10.1002/jso.21169
Evaluation of a peritoneal surface disease severity score in patients with colon cancer with peritoneal carcinomatosis
J. Pelz (2009)
10.1002/jso.23784
Poor outcome after cytoreductive surgery and HIPEC for colorectal peritoneal carcinomatosis with signet ring cell histology
T. V. van Oudheusden (2015)
10.1177/1457496915598759
Palliative Surgery for Pseudomyxoma Peritonei
J. Funder (2016)
10.1245/s10434-013-3053-z
Outcomes of Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients Older Than 70 Years; Survival Benefit at Considerable Morbidity and Mortality
K. Votanopoulos (2013)
10.3978/j.issn.2078-6891.2015.101
Peritoneal dissemination from high-grade appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
Kathleen A Cummins (2016)
10.1016/j.ejso.2012.03.001
Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: prognosis and treatment of recurrences in a cohort study.
P. Cashin (2012)
10.1245/s10434-010-1039-7
Peritoneal Carcinomatosis from Gastric Cancer: A Multi-Institutional Study of 159 Patients Treated by Cytoreductive Surgery Combined with Perioperative Intraperitoneal Chemotherapy
O. Glehen (2010)
10.1002/jso.21519
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat gastric cancer with ascites and/or peritoneal carcinomatosis: Results from a Chinese center
X. Yang (2010)
10.1097/COC.0b013e3182a0e867
Prognostic Significance of Ki67 Expression in Malignant Peritoneal Mesothelioma
K. Pillai (2015)
10.1200/JCO.2003.04.187
Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer.
V. Verwaal (2003)
10.1245/s10434-013-3328-4
Impact of Aggressive Histology and Location of Primary Tumor on the Efficacy of Surgical Therapy for Peritoneal Carcinomatosis of Colorectal Origin
J. Winer (2013)
10.1097/MNM.0000000000000649
The role of 18F-FDG-PET/ceCT in peritoneal mesothelioma
J. Dubreuil (2017)
10.1245/s10434-015-4892-6
Predictors of Severe Morbidity After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Patients With Colorectal Peritoneal Carcinomatosis
G. A. Simkens (2015)
10.1245/s10434-015-4962-9
The Role of Ki-67 and Pre-cytoreduction Parameters in Selecting Diffuse Malignant Peritoneal Mesothelioma (DMPM) Patients for Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
S. Kusamura (2015)
10.1111/his.12807
Prognostic significance of morphological growth patterns and mitotic index of epithelioid malignant peritoneal mesothelioma
A. Krasinskas (2016)
10.1245/s10434-007-9393-9
Prognostic Value of Circulating Tumor Markers in Patients with Pseudomyxoma Peritonei Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
D. Baratti (2007)
10.1245/s10434-012-2627-5
Significance of Serum Tumor Marker Levels in Peritoneal Carcinomatosis of Appendiceal Origin
P. Wagner (2012)
10.1097/DCR.0b013e3182a62b0d
Complete Cytoreduction for Pseudomyxoma Peritonei Is Optimal but Maximal Tumor Debulking May Be Beneficial in Patients in Whom Complete Tumor Removal Cannot Be Achieved
S. Dayal (2013)
10.1245/s10434-014-3798-z
The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 Patients with Colorectal Cancer with Peritoneal Carcinomatosis
J. Esquivel (2014)
10.1016/j.jamcollsurg.2010.10.016
Perioperative use of arginine-supplemented diets: a systematic review of the evidence.
J. Drover (2011)
10.1007/s12630-011-9652-x
Short-term preoperative smoking cessation and postoperative complications: a systematic review and meta-analysis
J. Wong (2011)
10.1186/1471-2407-10-689
Evaluation of Best Supportive Care and Systemic Chemotherapy as Treatment Stratified according to the retrospective Peritoneal Surface Disease Severity Score (PSDSS) for Peritoneal Carcinomatosis of Colorectal Origin
J. Pelz (2010)
10.1245/s10434-013-3049-8
Predicting Postoperative Morbidity Following Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (CS+HIPEC) with Preoperative FACT-C (Functional Assessment of Cancer Therapy) and Patient-Rated Performance Status
C. Ihemelandu (2013)
10.1002/14651858.CD002294.PUB4
Interventions for preoperative smoking cessation.
A. Møller (2005)
10.1245/s10434-006-9185-7
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in the Management of Peritoneal Surface Malignancies of Colonic Origin: A Consensus Statement
J. Esquivel (2006)
10.1245/s10434-015-4387-5
Extent of Colorectal Peritoneal Carcinomatosis: Attempt to Define a Threshold Above Which HIPEC Does Not Offer Survival Benefit: A Comparative Study
D. Goéré (2015)
10.1097/00000658-199402000-00001
Pseudomyxoma peritonei. A cancer whose biology is characterized by a redistribution phenomenon.
P. Sugarbaker (1994)
10.1056/NEJMOA010187
Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal Junction
J. Macdonald (2001)
10.1097/IGC.0000000000000327
Prognostic Significance of Sugarbaker’s Peritoneal Cancer Index for the Operability of Ovarian Carcinoma
Bjoern Lampe (2015)
10.1002/jso.23610
Cytoreductive surgery and hyperthermic intra‐peritoneal chemotherapy treatment of colorectal peritoneal metastases: Cohort analysis of high volume disease and cure rate
P. Cashin (2014)
10.1245/s10434-014-3713-7
Neoadjuvant Chemotherapy with Bevacizumab May Improve Outcome after Cytoreduction and Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) for Colorectal Carcinomatosis
W. Ceelen (2014)
10.1200/JCO.2011.39.7166
Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
T. Chua (2012)
10.1245/s10434-014-3506-z
A Simple Tumor Load-Based Nomogram for Surgery in Patients with Colorectal Liver and Peritoneal Metastases
D. Élias (2014)
10.1007/978-1-4613-1247-5_23
Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis.
P. Jacquet (1996)
10.1002/bjs.5863
Learning curve of combined modality treatment in peritoneal surface disease
R. M. Smeenk (2007)
10.1093/bja/aen401
Smoking and alcohol intervention before surgery: evidence for best practice.
H. Tønnesen (2009)
10.1016/j.ejso.2010.05.007
Curative treatment of colorectal peritoneal carcinomatosis: current status and future trends.
L. Maggiori (2010)
10.1002/JSO.20107
Utility of CEA and CA 19‐9 tumor markers in diagnosis and prognostic assessment of mucinous epithelial cancers of the appendix
C. Pablo Carmignani (2004)
10.1002/jso.23924
Incorporation of diagnostic laparoscopy in the management algorithm for patients with peritoneal metastases: A multi‐institutional analysis
P. Tabrizian (2015)
10.1002/(SICI)1097-0142(19970301)79:5<884::AID-CNCR3>3.0.CO;2-C
Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery
S. Fujimoto (1997)
10.1002/jso.23633
Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: Results of the GYMSSA trial
Udo Rudloff (2014)
10.1245/s10434-014-4335-9
Improved Survival with Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms
J. H. Choe (2014)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar